Clinical Trial Update: Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance. [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on Endostar in combination with chemotherapy and an EGFR-TKI for lung cancer patients with acquired resistance, in Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Endostar (recombinant human endostatin)

Snippet

Sponsor: Peking University Third Hospital | Conditions: Lung Cancer | Phase 2, Phase 3 | Status: UNKNOWN